Targeting splicing factors for cancer therapy.

Area of Science:

• Molecular Biology
• Cancer Biology
• Pharmacology

Background:

• Alternative splicing (AS) is a key regulator of eukaryotic gene expression.
• Misregulation of AS, often due to splicing factor dysfunction, contributes to cancer development and progression.
• Splicing factors are emerging as promising therapeutic targets for cancer treatment.

Purpose of the Study:

• To review current approaches for targeting splicing factors in cancer therapy.
• To discuss the advantages of targeting specific splicing factors over core spliceosome components.
• To suggest methods for enhancing the specificity of splicing factor modulators.

Main Methods:

• Review of existing literature on pharmacological modulators of splicing factors.
• Analysis of strategies targeting distinct splicing machinery components.
• Discussion of novel research directions in precision cancer therapy.

Main Results:

• Pharmacological modulators (small molecules, oligonucleotides) targeting splicing factors are under development.
• Targeting core spliceosome components can cause nonspecific and toxic effects.
• Focusing on specific splicing factors offers a more precise therapeutic approach.

Conclusions:

• Targeting specific splicing factors presents a promising avenue for developing more effective and less toxic cancer therapies.
• Improving the specificity of these targeted therapies is crucial for clinical success.
• Further research into novel strategies for modulating splicing factor function is warranted.